Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity

Simple item page
dc.contributor.authorPawar, Neelamen_US
dc.contributor.authorSomyashree, Den_US
dc.contributor.authorMeenakshi, Ren_US
dc.contributor.authorMaheshwari, Devendraen_US
dc.contributor.authorMohideen, Syeden_US
dc.contributor.authorUduman, Mohammed Sithiqen_US
dc.date.accessioned2023-08-25T06:37:26Z
dc.date.available2023-08-25T06:37:26Z
dc.date.issued2023-06
dc.description.abstractPurpose: To study the refractive profile of children after they received intravitreal injection of bevacizumab for retinopathy of prematurity (ROP). Methods: The study was conducted at a tertiary eye care hospital in South India. ROP patients of more than 1 year of age, presenting to the Pediatric Ophthalmology Clinic and Retina Clinic and having history of treatment for type ? ROP with intravitreal bevacizumab (IVB) or intravitreal bevacizumab and laser photocoagulation were included in the study. Cycloplegic refraction was done, and the refractive status was evaluated. The refractive status of age?matched, full?term children with uneventful perinatal and neonatal history was also recorded and compared to the study group. Results: Among 134 eyes of 67 study subjects, the major refractive error was myopia in 93 eyes (69.4%; spherical equivalent [SE] = ?2.89 ± 3.1, range = ?11.5 to ?0.5 D). There were 75 eyes (56%) with low?to?moderate myopia; high myopia was seen in 13.4%, emmetropia in 18.7%, and hypermetropia in 11.9% of eyes. The majority of them (87%) had with?the?rule (WTR) astigmatism. In 134 eyes, the SE was ?1.78 ± 3.2 (range = ?11.5 to 4 D); the SE of the 75 eyes with low?to?moderate myopia was ?1.53 ± 1.2 (range = ?0.50 to ?5 D). In the control group, the majority had emmetropia (91.8%). There was no significant association between the age at which IVB had been injected and the development of refractive errors (P = 0.078). The prevalence of low?to?moderate myopia was more than high myopia in patients with zone ? and zone ? ROP before treatment (60.0% and 54.5%, respectively). Conclusion: Myopia was the major refractive error seen in post?IVB pediatric patients. WTR astigmatism was more commonly seen. The age at which IVB injection had been given had no effect on the development of refractive errorsen_US
dc.identifier.affiliationsPediatric Ophthalmology and Squint Services, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, Indiaen_US
dc.identifier.citationPawar Neelam, Somyashree D, Meenakshi R, Maheshwari Devendra, Mohideen Syed, Uduman Mohammed Sithiq. Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity. Indian Journal of Ophthalmology. 2023 Jun; 71(6): 2561-2568en_US
dc.identifier.issn1998-3689
dc.identifier.issn0301-4738
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/225098
dc.languageenen_US
dc.publisherAll India Ophthalmological Societyen_US
dc.relation.issuenumber6en_US
dc.relation.volume71en_US
dc.source.urihttps://doi.org/10.4103/ijo.IJO_1209_22en_US
dc.subjectIntravitreal bevacizumaben_US
dc.subjectlaseren_US
dc.subjectmyopiaen_US
dc.subjectrefractive errorsen_US
dc.subjectROPen_US
dc.titleRefractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurityen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJO2023v71n6p2561.pdf
Size:
2.06 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Ophthalmology